Oxford Biomedica PLC OXB signs Agreement with Boehringer Ingelheim (4539U)
April 06 2021 - 1:00AM
UK Regulatory
TIDMOXB
RNS Number : 4539U
Oxford Biomedica PLC
06 April 2021
Oxford Biomedica signs a new three year Development & Supply
Agreement with Boehringer Ingelheim for the manufacture and supply
of viral vectors
Oxford, UK - 6 April, 2021: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group, announced today that it has signed a new three year
Development & Supply Agreement ("DSA") with Boehringer
Ingelheim for the manufacture and supply of various types of viral
vectors.
Under the terms of the DSA, Oxford Biomedica intends to
manufacture GMP batches for Boehringer Ingelheim to support the
development of viral vectors. The DSA also allows for the Group to
manufacture and supply viral vector products in the future.
John Dawson, Chief Executive Officer of Oxford Biomedica, said:
"This Development and Supply Agreement with Boehringer Ingelheim
demonstrates the good progress made in our partnership with
Boehringer Ingelheim, which started in 2018. We are proud to be
supporting another global pharmaceutical company in the development
and manufacturing of their viral vector programs.
"We now have a portfolio of partnerships spread across
development of CAR-Ts, TCR-Ts and in vivo gene therapeutics,
utilising lentiviral vectors. We are proud to partner with
Boehringer Ingelheim, a business with proven excellence in complex
manufacturing projects, as well as expertise in developing
innovative medicines for patients with serious unmet medical
needs."
-Ends-
Enquiries:
Oxford Biomedica plc T: +44 (0)1865 783 000
John Dawson, Chief Executive Officer T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer T: +44 (0)1865 954 161 / E: ir@oxb.com
Catherine Isted, Head of Corporate
Development & IR
T: +44 (0)20 3709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb, Sio
Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics,
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy
Consortium and Imperial Innovations, through which it has long-term
economic interests in other potential gene and cell therapy
products. Additionally the group has signed a 3 year master supply
and development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine, AZD1222.
Oxford Biomedica is based across several locations in Oxfordshire,
UK and employs more than 580 people. Further information is
available at www.oxb.com
Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that
improve the lives of humans and animals. As a leading
research-driven biopharmaceutical company, the company creates
value through innovation in areas of high unmet medical need.
Founded in 1885 and family-owned ever since, Boehringer Ingelheim
takes a long-term perspective. Around 52,000 employees serve more
than 130 markets in the three business areas, Human Pharma, Animal
Health, and Biopharmaceutical Contract Manufacturing. Learn more at
www.boehringer-ingelheim.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRDGGDSUUGDGBU
(END) Dow Jones Newswires
April 06, 2021 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024